Shorla Oncology Reports the Acquisition of Jylamvo from Therakind Targeting Oncology and Autoimmune Indications
Shots:
- Shorla Oncology entered into an agreement with Therakind under which Shorla has acquired Jylamvo (oral methotrexate solution) for the US market, a US FDA-approved (Nov 2022) therapy for the treatment of various indications incl. lymphoblastic leukemia, mycosis fungoides, r/r non-Hodgkin lymphoma, rheumatoid arthritis & severe psoriasis
- The acquisition was made by Shorla after raising $35M in Series B funding in order to accelerate the growth of its oncology portfolio by commercializing therapies that have faced shortages in the market
- Jylamvo, a folate analog metabolic inhibitor indicated for the treatment of various indications, has faced a shortage in the US market in other dosage forms
Ref: Businesswire | Image: Shorla Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
